The healthcare conglomerate’s revenue increased 10.6 percent from the previous year, reaching $20.8 billion in the second quarter. Analysts estimated J&J’s second-quarter revenue would hit $20.39 billion.
Net income was $4 billion in the second quarter, or $1.45 per share. However, excluding amortization expenses and other special items, the company earned $5.7 billion, or $2.10 per share, 3 cents above analyst estimates.
J&J’s successful financial results in the quarter were largely fueled by its pharmaceutical business, namely its cancer drugs. The pharma arm alone posted $10.4 billion in revenue, a 20 percent year-over-year increase. Worldwide sales of its oncology drugs increased 42.2 percent from the same quarter one year prior, to $2.45 billion.
In addition, J&J’s medical device unit increased 3.7 percent from the same quarter a year prior, hitting $7 billion.
The company’s namesake consumer health business, specifically its baby care line, has been a weakness. Revenue for this line declined 7.7 percent worldwide and 21 percent in the U.S. in the second quarter.
After J&J reported its second-quarter financial results, shares of the company soared 3.2 percent.
More articles on pharmacy:
Packaging concerns force Novartis, Sandoz to recall 12 drugs
Pfizer stock value dips after Trump’s tweet
8 lesser-known facts about Pfizer
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
